Jump to content

Glecaprevir

From Wikipedia, the free encyclopedia
Glecaprevir
Clinical data
Trade namesMavyret (combination with pibrentasvir)
Other namesABT-493
Routes of
administration
By mouth
ATC code
  • None
Pharmacokinetic data
Protein binding97.5%
MetabolismCYP3A
Elimination half-life6 hours
ExcretionFaeces (92.1%), urine (0.7%)
Identifiers
  • (3aR,7S,10S,12R,21E,24aR)-7-tert-Butyl-N-{(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19] [1,10,17,3,6]trioxadiazacyclonon adecino[11,12-b]quinoxaline-10-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H46F4N6O9S
Molar mass838.87 g·mol−1
3D model (JSmol)
  • CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O
  • InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
  • Key:MLSQGNCUYAMAHD-ITNVBOSISA-N

Glecaprevir (INN,[1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals.[2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.[3]

On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes (1–6) of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment.[4] In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.[5]

See also

[edit]

References

[edit]
  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 76" (PDF). World Health Organization. p. 503. Retrieved 25 February 2017.
  2. ^ Notman, Nina (August 14, 2023). "ACS names its 2023 Heroes of Chemistry". Chemical & Engineering News. Vol. 101, no. 26. Archived from the original on 2024-03-16. Retrieved 2024-04-04.
  3. ^ Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, et al. (December 2015). "Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection". Antimicrobial Agents and Chemotherapy. 60 (3): 1546–55. doi:10.1128/AAC.02264-15. PMC 4775945. PMID 26711747.
  4. ^ "AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C." AbbVie Inc. North Chicago, Illinois, U.S.A. December 19, 2016. Archived from the original on 20 August 2017. Retrieved 25 February 2017.
  5. ^ "Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17. Archived from the original (PDF) on 2017-10-19. Retrieved 2017-10-20.